Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent pediatric neurodevelopmental conditions, affecting between 3% and 7% of school-aged children (Felt et al., 2014). It is commonly treated using some combination of counseling, behavioral changes and pharmacological agents including stimulants. Various childfriendly intermediate- and long-acting formulations of methylphenidate and dexmethylphenidate are available; however, their use remains controversial (Krizinger et al., 2019).
Download Innovation Spotlight